Morningstar Investment Services’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-23,753
| Closed | -$1.68M | – | 168 |
|
|
2024
Q3 | $1.68M | Buy |
23,753
+951
| +4% | +$79.5K | 0.02% | 182 |
|
|
2024
Q2 | $1.9M | Buy |
22,802
+312
| +1% | +$26K | 0.02% | 166 |
|
|
2024
Q1 | $1.99M | Sell |
22,490
-22,112
| -50% | -$1.98M | 0.02% | 159 |
|
|
2023
Q4 | $4.33M | Buy |
44,602
+23,288
| +109% | +$2.06M | 0.02% | 161 |
|
|
2023
Q3 | $1.9M | Buy |
21,314
+661
| +3% | +$58.8K | 0.02% | 159 |
|
|
2023
Q2 | $1.85M | Buy |
20,653
+1,420
| +7% | +$134K | 0.02% | 156 |
|
|
2023
Q1 | $1.82M | Buy |
19,233
+1,163
| +6% | +$121K | 0.02% | 153 |
|
|
2022
Q4 | $1.88M | Buy |
18,070
+328
| +2% | +$30.8K | 0.03% | 145 |
|
|
2022
Q3 | $1.52M | Sell |
17,742
-1,132
| -6% | -$101K | 0.02% | 146 |
|
|
2022
Q2 | $1.58M | Buy |
18,874
+3,808
| +25% | +$303K | 0.02% | 153 |
|
|
2022
Q1 | $1.18M | Buy |
15,066
+2,613
| +21% | +$219K | 0.01% | 172 |
|
|
2021
Q4 | $1.1M | Buy |
12,453
+2,145
| +21% | +$177K | 0.01% | 174 |
|
|
2021
Q3 | $792K | Buy |
10,308
+996
| +11% | +$78.6K | 0.01% | 176 |
|
|
2021
Q2 | $777K | Buy |
9,312
+1,640
| +21% | +$130K | 0.01% | 176 |
|
|
2021
Q1 | $575K | Buy |
7,672
+4,056
| +112% | +$331K | 0.01% | 174 |
|
|
2020
Q4 | $317K | Sell |
3,616
-32
| -0.9% | -$2.54K | ﹤0.01% | 181 |
|
|
2020
Q3 | $278K | Buy |
3,648
+127
| +4% | +$12.8K | ﹤0.01% | 180 |
|
|
2020
Q2 | $430K | Sell |
3,521
-58
| -2% | -$5.76K | 0.01% | 164 |
|
|
2020
Q1 | $295K | Buy |
3,579
+98
| +3% | +$8.44K | 0.01% | 177 |
|
|
2019
Q4 | $294K | Sell |
3,481
-269
| -7% | -$20.3K | ﹤0.01% | 170 |
|
|
2019
Q3 | $253K | Sell |
3,750
-187
| -5% | -$14.4K | ﹤0.01% | 171 |
|
|
2019
Q2 | $337K | Sell |
3,937
-423
| -10% | -$36.2K | 0.01% | 184 |
|
|
2019
Q1 | $387K | Sell |
4,360
-636
| -13% | -$58.9K | 0.01% | 168 |
|
|
2018
Q4 | $425K | Sell |
4,996
-62
| -1% | -$5.9K | 0.01% | 158 |
|
|
2018
Q3 | $490K | Buy |
5,058
+532
| +12% | +$53.1K | 0.01% | 157 |
|
|
2018
Q2 | $426K | Buy |
4,526
+183
| +4% | +$16K | 0.01% | 161 |
|
|
2018
Q1 | $352K | Buy |
4,343
+247
| +6% | +$21.2K | 0.01% | 171 |
|
|
2017
Q4 | $365K | Sell |
4,096
-131
| -3% | -$11.4K | 0.01% | 172 |
|
|
2017
Q3 | $393K | Sell |
4,227
-78
| -2% | -$6.89K | 0.01% | 160 |
|
|
2017
Q2 | $391K | Sell |
4,305
-42
| -1% | -$3.82K | 0.01% | 158 |
|
|
2017
Q1 | $382K | Buy |
4,347
+1,375
| +46% | +$122K | 0.01% | 158 |
|
|
2016
Q4 | $246K | Buy |
2,972
+79
| +3% | +$6.79K | 0.01% | 174 |
|
|
2016
Q3 | $268K | Buy |
+2,893
| New | +$272K | 0.01% | 197 |
|
Other funds holding BMRN
EIM
Morningstar Investment Services's BMRN Position: Q4 2024 in Review
Morningstar Investment Services sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 23,753 shares — an estimated $1.68M sold.
Morningstar Investment Services first reported a position in BMRN in Q3 2016 and held it in 33 quarters. The position peaked at $4.33M in Q4 2023. 544 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.
- Morningstar Investment Services reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Morningstar Investment Services sold 23,753 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $1.68M.
- Morningstar Investment Services first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 33 quarters.
- Morningstar Investment Services's BioMarin Pharmaceuticals position peaked at $4.33M in Q4 2023.
- 544 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.
Based on Morningstar Investment Services's 13F filing for Q4 2024, filed 12 Feb 2025.